Last reviewed · How we verify
Triamcinolone acetonide plus ropivacaine
Triamcinolone acetonide plus ropivacaine is a Small molecule drug developed by Fang Luo. It is currently FDA-approved.
Triamcinolone acetonide plus ropivacaine, marketed by Fang Luo, is a combination drug currently available in the market. The key composition patent is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Triamcinolone acetonide plus ropivacaine |
|---|---|
| Sponsor | Fang Luo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy (NA)
- Frozen Shoulder and Hormone Replacement Therapy (PHASE4)
- Preemptive Co-infiltration of Triamcinolone Acetonide With Ropivacaine for Postoperative Pain in Major Spinal Surgery (PHASE4)
- Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain (NA)
- Pre-emptive Scalp Infiltration with Triamcinolone Acetonide Plus Ropivacaine for Post-Craniotomy Pain in Children (PHASE4)
- Rhomboid Intercostal and Subserratus Plane Block Versus Paravertebral Block for Thoracic Herpes Zoster (NA)
- Triamcinolone Ketorolac (TriKe) Knee Trial (PHASE4)
- Predicting Response to Interventional Pain Management Techniques in Chronic Low Back Pain in a Prospective Cohort.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone acetonide plus ropivacaine CI brief — competitive landscape report
- Triamcinolone acetonide plus ropivacaine updates RSS · CI watch RSS
- Fang Luo portfolio CI